Osteoclasts can no longer function without these proteins and bone resorption is substantially reduced.With decreased osteoclastic
activity, resorption sites are reduced.
Post-SCI 3 wk to 6 mo, the serum level of bone collagen I telopeptide was reported to be higher, indicating predominant osteoclastic
They preferentially bind to bone surfaces which are undergoing remodelling and are released by the bone matrix during reabsorbion, inhibiting osteoclastic
resorption now exceeds the ability of osteoblasts to build new bone, and mineralized bone collagen is removed before completing secondary mineralization.
RANKL (receptor activator of the nuclear factor-kB ligand) is a surface protein, part of the superfamily of TNF (tumoral necrosis factor), which when bound to their receptors (RANK) expressed in the osteoclastic
precursors stimulates its differentiation in mature osteoclast, increasing its bone resorption and causing hypercalcemia and osteoporosis.
The researchers in this study conlcuded that antioxidants may reduce the damaging effects of oxidative stress on bone mass by reducing the up regulated osteoclastic
differentiation and enhancing the down regulated osteoblastic differentiation.
Currently FDA-approved bisphosphonates, including Fosamax (alendronate), Actonel (risedronate), Didronel (etidronate), Boniva (ibandronate), and Reclast (Zometa) (zoledronate), are designed to strengthen bone by inhibiting normal osteoclastic
bone resorbing activity, which slows the loss of bone mineral density (BMD), allowing the trabecular architecture to stabilize.
Bone turnover improved selectively in women >70 years old, as assessed by the dualenergy x-ray absorptiometry (DEXA) technique and the decrease of osteoclastic
The principal action of bisphosphonates is inhibition of osteoclastic
bone resorption, but the potent nitrogen-containing aminobisphosphonates such as zoledronic acid, alendronate, pamidronate, rise-dronate, and ibandronate also have proinflammatory effects, with an acute phase reaction characterized by fever and flulike symptoms occurring following a first treatment with these drugs in more than one-third of patients (Clin.
The right mastoid process demonstrated osteoclastic
activity in the bone and the petrous portion exhibited signs of bone remodeling.
Findings may include a dense fibroblastic stroma, areas of cystic degeneration, osteoid, microfractures, haemorrhage, macrophages with hemosiderin, and multinucleated osteoclastic
They also appear to reduce bone resorption by inhibiting osteoclastic
vacuolar proton pumps.